Medical News

RSS

CVS Caremark board authorizes new $2 billion stock repurchase program

CVS Caremark Corporation today announced that its Board of Directors has approved a new share repurchase program for up to $2.0 billion of its outstanding common stock. The share repurchase authorization, which is effective immediately and expires at the end of 2011, permits the Company to effect the repurchases from time to time through a combination of open market repurchases, privately negotiated transactions, accelerated share repurchase transactions, and/or other derivative transactions.

14 Jun 2010

Medical marijuana advocates bypassing traditional approval, effectiveness regulations

NPR continues its examination of medical marijuana: "Fourteen states and the District of Columbia have launched a medical experiment that doesn't follow any of the rules of science. By approving the use of marijuana as a medicine — with varying kinds of restrictions — these jurisdictions are bypassing the federal government's elaborate processes for approving medicines."

14 Jun 2010

WoundVision launches bedside thermographic imaging system

WoundVision™, the healthcare industry pioneer in advanced wound detection technology, is introducing today a revolutionary predictive bedside thermographic imaging system. The WoundVision system brings knowledge bedside by acquiring, analyzing and applying essential patient data to inform healthcare providers in the development of effective treatment and care plans.

14 Jun 2010

BioAMD establishes headquarters at Daresbury SIC

Flex Fuels Energy, Inc. announced today that its subsidiary, BioAMD Holdings Ltd., has established its headquarters at the prestigious Daresbury Science and Innovation Campus in the United Kingdom. BioAMD is in the $12.6 billion Point-of-Care medical diagnostics industry.

14 Jun 2010

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today presented preclinical and clinical data on CAL-101, the Company's oral, delta selective PI3K inhibitor at the 15th Congress of the European Hematology Association in Barcelona, Spain.

14 Jun 2010

BioScale secures $25 million for commercialization of ViBE protein analytics systems

BioScale Inc., a privately-held life science company that develops, manufactures and promotes a new generation of protein analytics technology, today announced that it has secured $25 million in its recent financing round. Led by new investor Morningside Venture, this round will be used to expand manufacturing operations and commercial sales of the ViBE protein analytics systems. Also participating in the financing were existing investors New Science Ventures, WFD Ventures, F2 Ventures, and several individual investors

14 Jun 2010

Lantheus Medical Imaging reports new Phase 4 data from DEFINITY study

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced new data from a Phase 4, open-label safety study evaluating the effect of DEFINITY® Vial For (Perflutren Lipid Microsphere) Injectable Suspension, an echocardiography contrast agent, on pulmonary and systemic artery hemodynamics in patients with either normal or increased baseline pulmonary artery pressure.

14 Jun 2010

HCL Infosystems, Wellogic partner to create India's National Health Information Exchange Environment

HCL Infosystems, India's premier information technology company and Wellogic, a renowned healthcare interoperability and point-of-care solutions provider, today announced that they are working together to create India's National Health Information Exchange Environment (INHIEE), and seeding adoption via Wellogic's world-class portal, electronic health record (EHR), and personal health record (PHR) solutions.

14 Jun 2010

Healthcore Media launches dynamic, educational and community-oriented health website

Healthcore Media, LLC has launched http://www.onehealth.com, a dynamic, educational and community-oriented health website that is quickly taking center stage among health portals. Chronic illnesses are at an all-time high, and unbiased medical information and supportive connections with others are taking top priority across the world. One Health has answered the call.

14 Jun 2010

Faron, Priaxon enter collaboration to develop new AOC3/SSAO antagonists

Faron Pharmaceuticals Ltd., Turku, Finland and Priaxon AG, Munich, Germany today announced the entry into a collaboration and commercialization agreement to obtain new superior AOC3/SSAO antagonists. This collaboration combines two world-class technologies, the thorough understanding of the AOC3-protein and its ligand interaction with the rapid discovery engine for the development of new chemical inhibitors of protein-protein interactions.

14 Jun 2010

Updated Phase 1 trial results of blinatumomab in patients with relapsed NHL presented at EHA 2010

Micromet, Inc. today announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma. A high objective response rate was maintained among patients treated with blinatumomab using an adapted schedule, comparable to that previously reported in patients receiving constant dosing.

14 Jun 2010

Agile Therapeutics completes $45 million Series B Preferred Stock financing round

Agile Therapeutics, Inc., a late-stage pharmaceutical company specializing in women's healthcare products, today announced that it completed a $45 million Series B Preferred Stock financing. The financing round was co-led by Investor Growth Capital and Care Capital, with strong participation from ProQuest Investments. Kaiser Permanente Ventures and Novitas Capital also joined the financing round. Investor Growth Capital, Care Capital, and Kaiser Permanente Ventures are new investors to Agile.

14 Jun 2010

Oragenics awarded additional $500,000 to further development of MU 1140, DPOLT antibiotics platform

Oragenics, Inc., a biopharmaceutical company, announced today that the National Science Foundation has awarded the Company an additional $500,000 in funds to support the previously awarded SBIR Phase II grant for the Company's DPOLT Lantibiotic Synthesis Platform.

14 Jun 2010

PHC's Board of Directors authorize repurchase of up to one million shares of Class A common stock

PHC, Inc., d/b/a Pioneer Behavioral Health, a leading provider of inpatient and outpatient behavioral health services, announced today that its Board of Directors has authorized the repurchase of up to one million shares of its Class A common stock for a one-year period commencing July 1, 2010.

14 Jun 2010

DV Biologics executes agreement with System Biosciences to develop iPSC lines

DV Biologics LLC announced today that it has executed an agreement with System Biosciences LLC for the development of human-derived disease-specific induced pluripotent stem cell lines.

14 Jun 2010

FDA clears U.Va.'s SpermCheck Fertility at-home test

Couples will soon have a new tool in diagnosing male infertility - without the expense and inconvenience associated with a trip to a specialist's office.

14 Jun 2010

Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC

Telormedix, a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases, today announced the start of a Phase I/II clinical study of TMX-101 for the treatment of Non-Muscle Invasive Bladder Cancer. TMX-101 is an immunotherapeutic compound and Telormedix has already recruited the first patients for this clinical study.

14 Jun 2010

'Micro-ear' to screen for malaria, sleeping sickness

A team of researchers from the Universities of Glasgow and Oxford, and the UK's National Institute of Medical Research at Mill Hill, are developing a 'micro-ear' which may help develop medicines and screening for diseases such as malaria and sleeping sickness in Africa. The project is in two parts, explains Professor Jon Cooper, a bio-engineer at University of Glasgow.

14 Jun 2010

UBC earns high ratings in 2010 late phase market dynamics survey

United BioSource Corporation (UBC) today announced results from an independent survey that examined late phase product development services delivered by 34 contract research organizations and other scientific and medical affairs companies serving the biopharmaceutical industry. The report, titled 2010 Late Phase Market Dynamics and published by Industry Standard Research (ISR), provided data and analysis from a survey that captured information from 149 respondents, representing 95 companies.

14 Jun 2010

New research evaluating substantial disease burden of PNH presented at European Hematology Association

Alexion Pharmaceuticals, Inc. today announced new research evaluating the substantial disease burden of paroxysmal nocturnal hemoglobinuria, an ultra-rare blood disorder, in patients worldwide. The International PNH Registry, involving 580 patients from 99 sites in 14 countries as of May 2010, found that the debilitating symptoms and life-threatening complications of PNH are similar across patient populations around the world.

14 Jun 2010

Medical News

CVS Caremark board authorizes new $2 billion stock repurchase program

Medical marijuana advocates bypassing traditional approval, effectiveness regulations

WoundVision launches bedside thermographic imaging system

BioAMD establishes headquarters at Daresbury SIC

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

BioScale secures $25 million for commercialization of ViBE protein analytics systems

Lantheus Medical Imaging reports new Phase 4 data from DEFINITY study

HCL Infosystems, Wellogic partner to create India's National Health Information Exchange Environment

Healthcore Media launches dynamic, educational and community-oriented health website

Faron, Priaxon enter collaboration to develop new AOC3/SSAO antagonists

Updated Phase 1 trial results of blinatumomab in patients with relapsed NHL presented at EHA 2010

Agile Therapeutics completes $45 million Series B Preferred Stock financing round

Oragenics awarded additional $500,000 to further development of MU 1140, DPOLT antibiotics platform

PHC's Board of Directors authorize repurchase of up to one million shares of Class A common stock

DV Biologics executes agreement with System Biosciences to develop iPSC lines

FDA clears U.Va.'s SpermCheck Fertility at-home test

Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC

'Micro-ear' to screen for malaria, sleeping sickness

UBC earns high ratings in 2010 late phase market dynamics survey

New research evaluating substantial disease burden of PNH presented at European Hematology Association

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News